Bulk Orders 20+ vials
Volume pricing applies automatically from three vials and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulk
Bioregulator
Wolverine+ is a research blend of three peptides. It holds 10MG Cartalax, 5MG BPC-157, and 5MG TB-500. Labs use it to study connective tissue pathways and cell recovery models. Other areas include extracellular matrix biology, angiogenesis signals and tissue response.
Bundle & save
Referral program · researchers save 10%, you earn 15% backThe compounds researchers order most, by verified order volume.
More ways to save
Volume pricing applies automatically from three vials and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulkShipping batch WLV+01
Open the certificate matched to this shipping batch.
Verified test results
Each batch is analyzed by ILS Laboratories, an independent ISO/IEC 17025 accredited lab, before release. Below is the report for lot WLV+01, summarized from the certificate the lab published.
This lot ships under its own published certificate. Open any certificate below, exactly as the lab released it.
Side by side
Technical specifications
Peer-reviewed literature
Published research on each compound in this formulation, linked to its PubMed entry. Provided for educational reference only - not product claims.
Important research notice
Not for human, veterinary, or food use. This product is sold exclusively for laboratory research purposes. It is not intended to diagnose, treat, cure, or prevent any disease, and has not been evaluated by the FDA.
All referenced publications and registries are sourced from peer-reviewed journals and official registries. They are provided for educational reference only and are not product claims.
By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with all applicable laws and regulations.
Ready when you are
The lot on this page links to the signed certificate for that batch.
Lyophilized research material
Wolverine+ is a research blend of three peptides. It holds 10MG Cartalax, 5MG BPC-157, and 5MG TB-500. Labs use it to study connective tissue pathways and cell recovery models. Other areas include extracellular matrix biology, angiogenesis signals and tissue response. Work also covers cytoskeletal pathways and repair signals driven by peptides.
Disguised Alpha Wolverine+ puts three research peptides in one formula. It suits researchers who study signaling models that overlap. These include tissue response and matrix models. They also include structural support and cell adaptation.
| Cartalax | 10MG |
|---|---|
| BPC-157 | 5MG |
| TB-500 | 5MG |
| Total Peptide Content | 20MG |
| Formula Type | Multi-peptide research blend |
Used in models of connective tissue biology and cartilage signals. Also used for extracellular matrix pathways and cell control.
Used in tissue response, angiogenesis and gut barrier models. Also used for fibroblast activity, cell recovery and repair pathway research.
Used in models of actin regulation and cell migration. Also used for tissue response, cytoskeletal signals and cell repair pathways.
Wolverine+ is built around three research peptides. Their pathway interests complement each other. Labs study Cartalax in models of connective tissue signals. Cell settings linked to cartilage are also studied. Other models cover matrix regulation and gene expression pathways.
Labs study BPC-157 in models of tissue response signals and angiogenesis mechanisms. Gut barrier biology, fibroblast activity and cell recovery are other areas. Labs study TB-500 in models of actin control and cytoskeletal pathways. Cell migration, tissue response and repair signals are other areas.
Together, the blend gives a research framework that spans multiple pathways. It suits studies of connective tissue support systems and matrix behavior. Cell migration and tissue response fit too. This work is done under controlled test conditions.
Primary research relevant to the named compound or clearly identified component is linked below. Experimental results depend on identity, model and formulation.
Examined cell migration and FAK/paxillin signaling. The reported migration response should not be described as direct stimulation of cell proliferation.
Compared full-length thymosin beta-4 with a shorter region. Full-length thymosin beta-4 and a short TB-500 fragment are not interchangeable identities; check the lot-specific sequence.
Retain the product label and lot number with the research record. Review the matching certificate of analysis for test coverage and reported results. Identity, analytical purity, measured content, sterility and endotoxin testing are distinct assessments; one does not establish the others.
Follow the supplied label and your laboratory’s validated handling and storage procedures. Record the vehicle, concentration and preparation date where relevant. Dry-material stability does not establish the shelf life of a prepared solution.
The listed milligrams refer to material per vial, not concentration or administration instructions. A prepared solution has its own concentration and stability requirements. Verify the exact selected option and shipping lot.
Open the linked certificate for the assigned lot or use the COA portal. Check sample identity, methods, date and reported measurements. A report for another lot or formulation is not a substitute.
The references describe the materials and conditions used by their authors. They do not establish that this commercial formulation was tested. For blends, evidence on an individual component does not validate the finished mixture or establish synergy.
Three peptides: 10MG Cartalax, 5MG BPC-157 and 5MG TB-500. Cartalax is the synthetic tripeptide Ala-Glu-Asp, coded T-31 in earlier papers; BPC-157 is a 15-amino-acid partial sequence of a protein isolated from human gastric juice; and TB-500 names an acetylated thymosin beta-4 fragment or the full protein. No PubMed record names Cartalax with either one (searched 15 October 2026).
Wolverine+ adds Cartalax and holds half as much of each original peptide. Wolverine (BPC-157 / TB-500) combines BPC-157 and TB-500 in a 10MG/10MG research format, while Wolverine+ holds 10MG Cartalax, 5MG BPC-157 and 5MG TB-500, for 20MG of total peptide content.
Two of the three are named on the 2026 WADA Prohibited List, both in classes prohibited at all times: BPC-157 in section S0, non-approved substances, and thymosin-β4 and its derivatives, e.g. TB-500, under S2.3, growth factors and growth factor modulators. Cartalax is not named, but S0 also covers unlisted substances with no current approval for human therapeutic use.
This page sells Wolverine+, a multi-peptide research blend containing 10MG Cartalax, 5MG BPC-157, and 5MG TB-500, as a powder lyophilized in the USA. Each batch is analyzed by ILS Laboratories before release, and this lot ships under its own published certificate. It is sold exclusively for laboratory research purposes and ships from the US West Coast, by FedEx 2-Day shipping.
The current certificate is matched to the selected product option and assigned shipping batch.
Enable JavaScript to view the certificate for your selected option.
We share visit and purchase data with advertising partners to measure and show ads. Some US state laws, including California's, call that a sale or sharing of personal information. You can turn it off for this browser.
Ad sharing is on in this browser.
Saved in this browser only. For your account or other devices, email support@disguisedalpha.com. Privacy Policy